BRAF V600E
The most commonly actionable BRAF change, discussed with BRAF and MEK inhibitors.
Parent marker: BRAF
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
V600E activates the MAPK pathway. The combination of BRAF and MEK inhibitors is usually the framework for discussion, with different considerations in colorectal cancer.
How this finding appears in a report
Examined by targeted PCR, immunohistochemistry, or sequencing panel.
When therapy stops working
Reactivation of the MAPK pathway through changes in RAS or MEK is a frequently sought mechanism.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: BRAF
BRAF V600E in non-small-cell lung cancer is usually discussed within the framework of combination targeted therapy. These markers are also important in other cancers, including melanoma and colorectal cancer, with different approaches.
A negative result does not always mean absent
Summary
- Gen
- BRAF
- Variant
- BRAF V600E
- Alteration type
- Mutation
- Discussed in
- Lung Cancer, Colorectal Cancer
- Updated
- 2026-09-10
Other names in reports
V600E
Drugs discussed
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker BRAF
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT03340506Phase 4Targeted therapy
Dabrafenib and/or Trametinib Rollover Study
Lung Cancer | biomarker: BRAF | Targeted therapy
United States, Argentina, Austria +1130 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker BRAF, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03340506Not verified
NCT05786924Phase 1 / Phase 2Targeted therapy
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Lung Cancer | biomarker: KRAS, BRAF | Targeted therapy, Chemotherapy
United States, Australia, China +749 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05786924Not verified
NCT02693535Phase 2Combination regimen
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Multiple Myeloma | biomarker: BRAF | Immunotherapy, Targeted therapy
United States, Puerto Rico176 registry sites
Why this appears: Appears because it is recorded for Multiple Myeloma, it mentions marker BRAF, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT02693535Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- BRAF
Biomarker
Reason: Related through a biomarker
- Colorectal Cancer
Cancer type
Reason: Related to this page
- Lung Cancer
Cancer type
Reason: Related to this page
- Dabrafenib
Drug
Reason: Related to this page
- Encorafenib
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.